Combo HCV Promise Attracts Ascletis To Presidio Asset
This article was originally published in PharmAsia News
China's Ascletis has struck another deal with a foreign licensor, acquiring rights in China to a hepatitis C virus (HCV) candidate being developed by Presidio that it intends to investigate in an all-oral, interferon-free combination.
You may also be interested in...
Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.